Revance Net Income Over Time
| RVNC Stock | USD 3.80 0.07 1.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Revance Performance and Revance Correlation. Revance |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.34) | Revenue Per Share 2.656 | Quarterly Revenue Growth 0.107 | Return On Assets (0.24) | Return On Equity (20.97) |
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Revance and related stocks such as DiaMedica Therapeutics, Akero Therapeutics, and Nuvalent Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAC | (640 K) | (6.6 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.4 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (19.4 M) | (18.4 M) |
| AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.7 M) | (108.9 M) | (151.8 M) | (144.2 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (119.9 M) |
| IMCR | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (103.9 M) | (74.1 M) | (131.5 M) | (41.2 M) | (55.3 M) | (58.1 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.5 M) | (78.4 M) | (108 M) | (193 M) | (183.3 M) |
| ACLX | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (32.1 M) | (63.9 M) | (186.1 M) | (70.7 M) | (74.2 M) |
| ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (57.4 M) | (49.5 M) | (90.1 M) | (102 M) | (142.2 M) | (135.1 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | 185 K | (39.7 M) | (17.9 M) | (121.5 M) | (161.3 M) | (153.3 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (10.8 M) | (46.5 M) | (27.1 M) | (51 M) | (127.5 M) | (309.8 M) | (344.9 M) | (746.4 M) | (652.2 M) | (528.6 M) | (502.2 M) |
| DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (179.5 M) |
| BPMC | (20.9 M) | (20.9 M) | (20.9 M) | (20.9 M) | (40.3 M) | (52.8 M) | (72.5 M) | (148.1 M) | (236.6 M) | (328.7 M) | 313.9 M | (644.1 M) | (557.5 M) | (507 M) | (481.6 M) |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (28.5 M) | (50.6 M) | (84.7 M) | (93.1 M) | (104.7 M) | (99.5 M) |
Revance and related stocks such as DiaMedica Therapeutics, Akero Therapeutics, and Nuvalent Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Revance financial statement analysis. It represents the amount of money remaining after all of Revance operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Revance | RVNC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.8
Check out Revance Performance and Revance Correlation. For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Revance technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.